Oncology – Page 20 – Medical News Asia

Do you know your lifetime risk on Pancreatic Cancer?

20 November 2017/0 Comments/in Gastrointestinal Cancer, Oncology/by Stijn van den Borne, MSc

November turns purple for pancreatic cancer awareness. Focus is on one of the most difficult-to-treat tumours with the final objective: to double the survival of pancreatic cancer by 2020. What is your risk to develop pancreatic cancer? And how likely are you to get cured of the disease?

Luminal Breast Cancer: can CDK4/6 Inhibition by Palbociclib Improve on Chemotherapy?

25 October 2017/1 Comment/in Breast Cancer, Oncology, Endocrine Therapy/by Stijn van den Borne, MSc

Can chemotherapy be avoided in women with hormone-sensitive breast cancer? This is a prominent question in the treatment of breast cancer around the globe.

Pembrolizumab approved for advanced gastric cancer

22 September 2017/0 Comments/in Gastrointestinal Cancer, US FDA Onc\Haem Approvals, Chemotherapy, Immunotherapy, Translational Research/by Stijn van den Borne, MSc

On September 22, 2017, the FDA granted accelerated approval to pembrolizumab (KEYTRUDA, Merck) for use in patients with locally advanced or metastatic, gastric or gastroesophageal junction (GEJ) adenocarcinoma positive for PD-L1 as determined by an FDA-approved companion diagnostic (CDx) and progressing after ≥2 prior systemic therapies, including a fluoropyrimidine- and platinum-containing regimen, and, when appropriate, HER2-targeted therapy.

Nivolumab approved for sorafenib-refractory HCC

22 September 2017/in Gastrointestinal Cancer, US FDA Onc\Haem Approvals, Immunotherapy, Targeted Therapies/by Stijn van den Borne, MSc

On September 22, 2017, the Food and Drug Administration granted accelerated approval to nivolumab (OPDIVO, Bristol-Myers Squibb Co.) for the treatment of hepatocellular carcinoma (HCC) in patients who have been previously treated with sorafenib. Approval was based on a 154-patient subgroup of CHECKMATE-040 (NCT 01658878), a multicenter, open-label trial conducted in patients with HCC and […]

Should all Women with Endocrine-Sensitive and Operable Breast Cancer Receive Adjuvant Hormonal Therapy?

5 July 2017/0 Comments/in Breast Cancer, Oncology, Endocrine Therapy/by Stijn van den Borne, MSc

One in six women with early, operable breast cancer may not need years of adjuvant hormonal therapy after primary treatment. This was the conclusion of a recent study published in JAMA (the Journal of the American Medical Association) Oncology.

Interested in Attending an Immunooncology Conference?

21 June 2017/0 Comments/in Conferences, Oncology, Immunotherapy, Translational Research/by Stijn van den Borne, MSc

The CICS Annual Conference on Immuno Oncology is offering the most significant advances in the world of oncology. The goal of the meeting is to convey the clinical and translational advances in various areas of cancer immunology to medical oncologists, medical students, and other health professionals.

ESMO16 Breast Cancer: Palbociclib, Ribociclib and Abemaciclib Data

9 November 2016/2 Comments/in Breast Cancer, Conferences, Oncology, Endocrine Therapy/by Stijn van den Borne, MSc

Cyclin-dependent Kinase 4 and 6 (CDK4/6) inhibitors have shown clinical activity in patients with endocrine-resistant metastatic breast cancer. During the European Society for Medical Oncology (ESMO) Annual Meeting 2016, significant updates on studies with CDK4/6 inhibitors ribociclib, palbociclib and abemaciclib were presented.

PD-L1 Biomarker: a Comparison of ASCO2016 PD-1 and PD-L1 Data

26 October 2016/Enter your password to view comments./in Gastrointestinal Cancer, Genitourinary Cancer, Haematology, Head and Neck Cancer, Lung Cancer, Melanoma & Skin Cancer, Immunotherapy, Pathology, Translational Research/by Stijn van den Borne, MSc

There is no excerpt because this is a protected post.

Novel Biomarker for Ipilimumab Treatment may aid Future Patient Selection in Several Malignancies

24 October 2016/4 Comments/in Oncology, Immunotherapy, Pathology, Translational Research/by Stijn van den Borne, MSc

The number of different types of T-helper cells (Th) and cytotoxic T cells (CD8) may predict response to ipilimumab in several malignancies. This was concluded by Dr Juan Pablo Márquez Manríquez who presented the study at the ESMO conference on behalf of the investigators of the Sonora Cancer Research Center (CICS) in Mexico and the United States (U.S.).

ESMO16 Ipilimumab data – Download the PPT

11 October 2016/Enter your password to view comments./in Conferences, Oncology, Melanoma & Skin Cancer, Immunotherapy/by Stijn van den Borne, MSc

There is no excerpt because this is a protected post.